Abstract
This paper presents a meta-analysis regarding the detection rate (DR) of fluorine-18 ((18)F)-labeled prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) in the management of patients with prostate cancer (PCa). Relevant studies regarding (18)F-PSMA PET/CT in the management of PCa published until June 1, 2021, were electronically searched in online databases including EMBASE, PubMed, and Web of Science. The primary outcome was the DR of (18)F-PSMA PET/CT in managing PCa patients, while the secondary outcome was the DR of (18)F-PSMA PET/CT according to Gleason scores and serum prostate-specific antigen (PSA) level. The pooled DR was calculated on a per-patient basis, with pooled odd ratios and 95% confidence intervals (CIs). In total, 17 observational studies evaluating 1019 patients with PCa met the inclusion criteria. The DR of (18)F-PSMA PET/CT was 0.83 (95% CI: 0.78-0.88), in the random-effects model. Subsequently, the analysis of DR of (18)F-PSMA PET/CT in PCa patients using Gleason score (≤7 vs ≥8), showed a significant difference in PCa patients. Based on the above results, the higher Gleason score of PCa patients, the higher DR of (18)F-PSMA PET/CT. The DR of (18)F-PSMA PET/CT in PCa was 0.57 for PSA <0.5 ng ml(-1); 0.75 for PSA ≥0.5 ng ml(-1) and <1.0 ng ml(-1); 0.93 for PSA ≥1.0 ng ml(-1) and <2.0 ng ml(-1); and 0.95 for PSA ≥2.0 ng ml(-1). Therefore, the significant diagnostic value was found in terms of the DR of (18)F-PSMA PET/CT in managing PCa patients and was associated with Gleason score and serum PSA level.